Last €70.10 EUR
Change Today +1.86 / 2.73%
Volume 2.4K
ALCAR On Other Exchanges
Symbol
Exchange
EN Paris
Frankfurt
OTC US
As of 11:21 AM 10/20/14 All times are local (Market data is delayed by at least 15 minutes).

carmat (ALCAR) Snapshot

Open
€69.79
Previous Close
€68.24
Day High
€70.87
Day Low
€69.46
52 Week High
12/23/13 - €147.40
52 Week Low
10/16/14 - €61.22
Market Cap
300.3M
Average Volume 10 Days
5.4K
EPS TTM
€-3.51
Shares Outstanding
4.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CARMAT (ALCAR)

Related News

No related news articles were found.

carmat (ALCAR) Related Businessweek News

No Related Businessweek News Found

carmat (ALCAR) Details

Carmat Société Anonyme engages in designing and developing an implantable artificial heart. The company is developing orthotopic and biocompatible artificial heart, as well as its electrical power supply system and remote diagnosis system for patients suffering from chronic terminal heart failures. Carmat Société Anonyme was founded in 2008 and is based in Velizy Villacoublay, France.

39 Employees
Last Reported Date: 03/17/14
Founded in 2008

carmat (ALCAR) Top Compensated Officers

Chief Executive Officer, Director General, Ge...
Total Annual Compensation: €385.0K
Compensation as of Fiscal Year 2012.

carmat (ALCAR) Key Developments

CARMAT Appoints Eric Richez to Director of Business Development

CARMAT has strengthened its management team by appointing Mr. Eric Richez as Director of Business Development. Eric's first task will be to define CARMAT's market access strategy. He will be working closely with the Medical department to manage the Company's relationships with its investigation centers and to develop training centers. Working with senior management and the Marketing department, he will contribute to the planning and execution of reimbursement and marketing strategies. Eric Richez (53 years) has been working his entire career in the medical device industry in Europe in various sales, marketing and business development positions and in particular in the circulatory assist market. He spent 13 years in various sales and marketing positions at Thoratec.

Carmat Société Anonyme, Annual General Meeting, Apr 02, 2014

Carmat Société Anonyme, Annual General Meeting, Apr 02, 2014.

Carmat Announces Continuation of the Clinical Trial on the First Bioprosthetic Artificial Heart

Carmat announced the continuation of the initial first-in-man clinical trial of its bioprosthetic artificial heart, in accordance with the applicable regulatory agreements. Following the announcement of the death, two and a half months after the implantation of the artificial heart, of the first patient, aged 76, CARMAT first and foremost wishes to pay tribute to the courage and the pioneering role of this patient and his family, and to thank the medical team's dedication and their contribution to this world first. The company would like to point out that this first implantation is part of an approved feasibility study involving four patients in an immediate life-threatening situation. Given these specific conditions, the clinical monitoring of a patient for 30 days or more after the artificial heart is implanted is considered to be encouraging. The first bioprosthetic heart, designed by Professor Alain Carpentier and developed in collaboration with CARMAT, beat for 74 days, that is some 7 million times, following its implantation on December 18, 2013 at the Georges Pompidou European Hospital in Paris. An analysis of the data is being carried out in accordance to the clinical trial's protocol. The company stresses that it is too soon to draw any conclusions from the data of a single patient, whatever the duration of the implantation.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALCAR:FP €70.10 EUR +1.86

ALCAR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALCAR.
View Industry Companies
 

Industry Analysis

ALCAR

Industry Average

Valuation ALCAR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 94.4x
Price/Book 18.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 88.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARMAT, please visit www.carmatsas.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.